Loading video...

Video Failed to Load

Go Home

NEW Exclusive Interview: This miracle pill could make dogs live longer, with Celine Halioua, Founder & CEO of Loyal Celine Halioua is building the first drug ever FDA-approved for lifespan extension itself — starting with dogs. We sat down on Onward to talk about why she thinks longevity is...

BenMillerise's profile picture

Benjamin Miller

11,366 subscribers

12,950 views • 3 months ago •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

10 Comments

Molly O’Shea's profile picture
Molly O’Shea3 months ago

@celinehalioua BREAKING: Dogs will now outlive humans

Benjamin Miller's profile picture
Benjamin Miller3 months ago

VIDEO: This miracle pill could make dogs live longer, with Celine Halioua, Founder & CEO of Loyal Spotify: Apple:

Jarrod Pasyanos's profile picture
Jarrod Pasyanos3 months ago

@fundrisefan @celinehalioua Let’s go! Save the dogs 🐶

vincenzo (fundrise fan)'s profile picture
vincenzo (fundrise fan)3 months ago

@celinehalioua these 4 will be listening prosperitas populo pupisque! #nossos

Brandon Jenkins's profile picture
Brandon Jenkins3 months ago

@celinehalioua So good!

Andrew - PhaseOne_big’s alt's profile picture
Andrew - PhaseOne_big’s alt3 months ago

@celinehalioua Haven’t listened to this yet but on its face this might be the smartest brand strategy of all time.

vincenzo (fundrise fan)'s profile picture
vincenzo (fundrise fan)3 months ago

@celinehalioua $VCX - #fundrise innovation fund - #VCX

Steven Smith's profile picture
Steven Smith3 months ago

@celinehalioua May GOD BLESS YOU into eternity for your work! We lost our sweet boy Berner one month before his 7th birthday due to lymphoma. Your work will help extend the love of the large breeds (and hopefully all breeds) for years of beautiful, loving companionship. THANK YOU!

theAmericanManual's profile picture
theAmericanManual3 months ago

@celinehalioua "Could" - sounds like left wing media.

kadari dayakar's profile picture
kadari dayakar3 months ago

@celinehalioua Hello Ben you're a scammer

Related Videos

In 2026, it's quite likely that a pill will hit the market which makes dogs live longer. This is a big deal for many reasons. The pill will come from Loyal and Celine Halioua. And they have more therapies in the pipeline. In this episode, we chat about Celine's life and career and Loyal's unique work in the longevity field. The Core Memory podcast - which makes people smarter - is brought to you by the finance wizards at Brex and the genius investors E1 Ventures 🇺🇸. Enjoy! Timestamps 00:00 – Intro 02:47 – Why Start With Dogs 06:05 – Aging Science Explained 09:12 – Inside FDA Trials 13:18 – Designing a Longevity Drug 17:42 – Metabolism and Aging 22:35 – Lessons From Biotech 26:48 – Building Loyal 31:54 – From Neuroscience to Founder 38:19 – GLP-1 vs Longevity Drugs 43:28 – Ethics of Longer Life 49:44 – What Dog Data Shows 54:59 – Longevity Hype & Peptides 59:47 – Biotech Needs Artists 01:05:20 – Investor Hype vs Reality 01:11:35 – AI in Drug Discovery 01:17:49 – Future of Aging Research 01:23:05 – Dogs and the End of Aging
1:29:44

In 2026, it's quite likely that a pill will hit the market which makes dogs live longer. This is a big deal for many reasons. The pill will come from Loyal and Celine Halioua. And they have more therapies in the pipeline. In this episode, we chat about Celine's life and career and Loyal's unique work in the longevity field. The Core Memory podcast - which makes people smarter - is brought to you by the finance wizards at Brex and the genius investors E1 Ventures 🇺🇸. Enjoy! Timestamps 00:00 – Intro 02:47 – Why Start With Dogs 06:05 – Aging Science Explained 09:12 – Inside FDA Trials 13:18 – Designing a Longevity Drug 17:42 – Metabolism and Aging 22:35 – Lessons From Biotech 26:48 – Building Loyal 31:54 – From Neuroscience to Founder 38:19 – GLP-1 vs Longevity Drugs 43:28 – Ethics of Longer Life 49:44 – What Dog Data Shows 54:59 – Longevity Hype & Peptides 59:47 – Biotech Needs Artists 01:05:20 – Investor Hype vs Reality 01:11:35 – AI in Drug Discovery 01:17:49 – Future of Aging Research 01:23:05 – Dogs and the End of Aging

Ashlee Vance

63,172 views • 10 months ago

We were an early investor in Celine Halioua's first round at Loyal — when it was just her, an idea, and a "poorly designed slide deck" (her words). Six years later: $250M+ raised, FDA efficacy and safety milestones cleared, and the largest clinical trial in animal health history. I sat down with Celine to talk about the whole journey — how she raised a quarter billion dollars pre-revenue, why dogs are the fastest path to a human longevity drug, and what the future of Loyal looks like as the drugs get closer to hitting the market. Congrats to Celine and the Loyal team on the $100M Series C!
0:40

We were an early investor in Celine Halioua's first round at Loyal — when it was just her, an idea, and a "poorly designed slide deck" (her words). Six years later: $250M+ raised, FDA efficacy and safety milestones cleared, and the largest clinical trial in animal health history. I sat down with Celine to talk about the whole journey — how she raised a quarter billion dollars pre-revenue, why dogs are the fastest path to a human longevity drug, and what the future of Loyal looks like as the drugs get closer to hitting the market. Congrats to Celine and the Loyal team on the $100M Series C!

Sam Kirschner

10,949 views • 7 months ago

Today I am launching the Free Radicals podcast with Eric Dai . Every Tuesday, we’ll be releasing long form conversations with the visionaries giving humanity control over biology and working to dramatically extend human lifespan. We’re thrilled to host Celine Halioua, Founder + CEO Loyal, for our inaugural episode. Celine is building the world’s first lifespan extension drugs for dogs. Follow me, Eric Dai and Free Radicals for new episodes every Tuesday. 00:00:00 - Intro 00:01:51 - Celine’s background 00:05:00 - Dropping out of academia 00:07:50 - Finding ways to increase free will 00:09:36 - How to align financial incentives with longevity 00:14:52 - Longevity drugs should be boring 00:21:24 - Celine’s leadership style 00:24:08 - Advice on fundraising and constructing feedback loops 00:26:52 - Loyal’s fundraising history 00:27:57 - Building for Zero Billion Dollar Markets 00:29:11 - How to succeed in biotech 00:30:21 - How to find blockbuster opportunities 00:33:25 - How to create a gold rush in longevity 00:35:25 - The problem with the aging field 00:39:32 - How to identify signal from noise 00:41:54 - AI applications to biology 00:45:15 - Importance of naiveté 00:47:24 - FREE RADICALS
47:57

Today I am launching the Free Radicals podcast with Eric Dai . Every Tuesday, we’ll be releasing long form conversations with the visionaries giving humanity control over biology and working to dramatically extend human lifespan. We’re thrilled to host Celine Halioua, Founder + CEO Loyal, for our inaugural episode. Celine is building the world’s first lifespan extension drugs for dogs. Follow me, Eric Dai and Free Radicals for new episodes every Tuesday. 00:00:00 - Intro 00:01:51 - Celine’s background 00:05:00 - Dropping out of academia 00:07:50 - Finding ways to increase free will 00:09:36 - How to align financial incentives with longevity 00:14:52 - Longevity drugs should be boring 00:21:24 - Celine’s leadership style 00:24:08 - Advice on fundraising and constructing feedback loops 00:26:52 - Loyal’s fundraising history 00:27:57 - Building for Zero Billion Dollar Markets 00:29:11 - How to succeed in biotech 00:30:21 - How to find blockbuster opportunities 00:33:25 - How to create a gold rush in longevity 00:35:25 - The problem with the aging field 00:39:32 - How to identify signal from noise 00:41:54 - AI applications to biology 00:45:15 - Importance of naiveté 00:47:24 - FREE RADICALS

Daniel Shur

29,572 views • 10 months ago

E182: Jordi Visser - Why Aging is a disease, Why Bitcoin is a hedge against abundance and why you shouldn't buy a house! Jordi Visser spent three decades on Wall Street, from a Morgan Stanley trading desk to CIO at Weiss Multi-Strategy. These days he studies AI, macro, and longevity full time. We cover why he thinks aging is optional, why Bitcoin is the only asset he'd bet on for the next decade, and why money never actually made him happy. 00:00 Intro 02:10 Jordi's Weekend Recap 03:49 The Blueprint For Living To 100 04:31 Why Longevity Became An Obsession 05:44 What Kills A Healthy Habit 07:20 Supplements & Meds: Worth It? 09:51 Partnerships: Variational Bitwise 10:44 The First Step Into Longevity 12:17 Wealth's Hidden Effect On Longevity 14:03 Peptides & Hormones: Jordi's Take 17:47 What Is Heart-Rate Variability? 21:21 How To Track Your HRV 23:17 Average vs. Great HRV 25:12 Lessons From The Finance World 29:10 Learning What Money Really Means 31:58 Partnership: KAST 32:47 Why Make More Money At All 35:20 "AI Will Make Everything Abundant" 38:20 Does Abundance Mean Cheaper? 38:54 Why We'll Still Need Wealth 41:22 How Jordi Fell Into Bitcoin 47:44 Jordi's Bitcoin Thesis, Simplified 50:10 How Much Bitcoin Is In His Portfolio 50:48 Would Jordi Ever Sell? 51:52 Partnerships: Jupiter Ethena 52:38 How Big Can Bitcoin Get 54:00 On "Bitcoin Is Too Expensive" 55:28 Why A Crypto Channel, Not Just Bitcoin 56:25 Does Jordi Own Other Crypto 57:24 Other Scarce Assets He's Bought 58:41 Should 20-Somethings Buy A House 01:02:00 Routine vs. Unique 01:03:57 Why Allergies Aren't Real 01:07:02 Closing Thoughts
1:07:34

E182: Jordi Visser - Why Aging is a disease, Why Bitcoin is a hedge against abundance and why you shouldn't buy a house! Jordi Visser spent three decades on Wall Street, from a Morgan Stanley trading desk to CIO at Weiss Multi-Strategy. These days he studies AI, macro, and longevity full time. We cover why he thinks aging is optional, why Bitcoin is the only asset he'd bet on for the next decade, and why money never actually made him happy. 00:00 Intro 02:10 Jordi's Weekend Recap 03:49 The Blueprint For Living To 100 04:31 Why Longevity Became An Obsession 05:44 What Kills A Healthy Habit 07:20 Supplements & Meds: Worth It? 09:51 Partnerships: Variational Bitwise 10:44 The First Step Into Longevity 12:17 Wealth's Hidden Effect On Longevity 14:03 Peptides & Hormones: Jordi's Take 17:47 What Is Heart-Rate Variability? 21:21 How To Track Your HRV 23:17 Average vs. Great HRV 25:12 Lessons From The Finance World 29:10 Learning What Money Really Means 31:58 Partnership: KAST 32:47 Why Make More Money At All 35:20 "AI Will Make Everything Abundant" 38:20 Does Abundance Mean Cheaper? 38:54 Why We'll Still Need Wealth 41:22 How Jordi Fell Into Bitcoin 47:44 Jordi's Bitcoin Thesis, Simplified 50:10 How Much Bitcoin Is In His Portfolio 50:48 Would Jordi Ever Sell? 51:52 Partnerships: Jupiter Ethena 52:38 How Big Can Bitcoin Get 54:00 On "Bitcoin Is Too Expensive" 55:28 Why A Crypto Channel, Not Just Bitcoin 56:25 Does Jordi Own Other Crypto 57:24 Other Scarce Assets He's Bought 58:41 Should 20-Somethings Buy A House 01:02:00 Routine vs. Unique 01:03:57 Why Allergies Aren't Real 01:07:02 Closing Thoughts

MR SHIFT 🦁

139,580 views • 1 month ago

One of the most exciting (and challenging) applications of physical AI is thinking about how it can accelerate scientific discovery. Imagine a robot that can pipette, handle stem cells, operate existing lab machinery, 24/7 - a physical AI scientist. This is what the new episode of Greylock Partners Change Agents is all about, featuring Michelle Lee, founder and CEO of Medra. We talk about building an AI-powered lab, how accelerating physical AI lab experimentation is the key to unlocking drug development, and how Medra is automating experimentation today inside pharma companies. 00:00 Teaser 00:56 Medra’s founding mission 04:17 Hypotheses are not enough 13:27 Medra’s differentiation 20:22 The experimentation bottleneck 27:06 Refining the agent harness 29:05 The role of the physical lab 33:23 Managing context across different customers 34:59 Working with models 40:26 Towards personalized medicine and drug discovery 43:15 AWS for life sciences Thank you for joining Michelle Lee
46:43

One of the most exciting (and challenging) applications of physical AI is thinking about how it can accelerate scientific discovery. Imagine a robot that can pipette, handle stem cells, operate existing lab machinery, 24/7 - a physical AI scientist. This is what the new episode of Greylock Partners Change Agents is all about, featuring Michelle Lee, founder and CEO of Medra. We talk about building an AI-powered lab, how accelerating physical AI lab experimentation is the key to unlocking drug development, and how Medra is automating experimentation today inside pharma companies. 00:00 Teaser 00:56 Medra’s founding mission 04:17 Hypotheses are not enough 13:27 Medra’s differentiation 20:22 The experimentation bottleneck 27:06 Refining the agent harness 29:05 The role of the physical lab 33:23 Managing context across different customers 34:59 Working with models 40:26 Towards personalized medicine and drug discovery 43:15 AWS for life sciences Thank you for joining Michelle Lee

Corinne Marie Riley

39,467 views • 14 days ago

"Aging is the process of a complex system slowly falling into its chaotic disequilibrium. And it's not like evolution necessarily even set a lifespan for us. It is merely the result of, once the system has been established, how long its intrinsic property stayed ordered before it became disordered." I’m excited to share my conversation with Jacob Kimmel of NewLimit. Every species who has ever lived has one shared certainty: we’ll age, decay, and die. Jacob and his team are among the small group of people on earth with the expertise and funding to work on this problem. We talked about why we age, whether cellular aging can actually be reversed, how evolution shaped our lifespan and our peaks, and how AI is fundamentally changing the next era of science. Recorded at New Limit’s HQ in South San Francisco. Timestamps: 00:00 Intro 01:25 Why Evolution Limits Lifespan 03:13 Evolution Tradeoffs Explained 07:44 Why Women Live Longer 10:15 Lessons from Long Lived Species 16:20 Peak Intelligence 23:26 What is Aging? 27:59 Yamanaka Factors 32:18 New Limit 33:56 AI's Role in Progress 37:28 Organ by Organ Longevity 40:28 Is Immortality Possible? 42:04 Lifespan Progress 45:44 How to Test Longevity Drugs 49:30 Placebo Mind Body Link 53:56 What longevity hacks actually work? 57:25 Peptides And Stem Cells 01:00:34 Gene Editing 01:05:10 Personalized Medicine 01:08:48 Philosophical Dilemmas of Longer Lifespans 01:14:57 Living Off Earth 01:16:55 AI And Bio Risks
1:23:37

"Aging is the process of a complex system slowly falling into its chaotic disequilibrium. And it's not like evolution necessarily even set a lifespan for us. It is merely the result of, once the system has been established, how long its intrinsic property stayed ordered before it became disordered." I’m excited to share my conversation with Jacob Kimmel of NewLimit. Every species who has ever lived has one shared certainty: we’ll age, decay, and die. Jacob and his team are among the small group of people on earth with the expertise and funding to work on this problem. We talked about why we age, whether cellular aging can actually be reversed, how evolution shaped our lifespan and our peaks, and how AI is fundamentally changing the next era of science. Recorded at New Limit’s HQ in South San Francisco. Timestamps: 00:00 Intro 01:25 Why Evolution Limits Lifespan 03:13 Evolution Tradeoffs Explained 07:44 Why Women Live Longer 10:15 Lessons from Long Lived Species 16:20 Peak Intelligence 23:26 What is Aging? 27:59 Yamanaka Factors 32:18 New Limit 33:56 AI's Role in Progress 37:28 Organ by Organ Longevity 40:28 Is Immortality Possible? 42:04 Lifespan Progress 45:44 How to Test Longevity Drugs 49:30 Placebo Mind Body Link 53:56 What longevity hacks actually work? 57:25 Peptides And Stem Cells 01:00:34 Gene Editing 01:05:10 Personalized Medicine 01:08:48 Philosophical Dilemmas of Longer Lifespans 01:14:57 Living Off Earth 01:16:55 AI And Bio Risks

Sabrina Halper

21,892 views • 2 months ago

NEW episode! Drug development has never been more expensive, in terms of output per dollar spent. This trend, called Eroom’s law, is surprising, considering the incredible technological advances in drug discovery, from genome sequencing to engineering to microscopy. On a new episode of the Works in Progress podcast, Ben Southwood and I talk to Ruxandra Teslo 🧬 about why this has happened and what can be done about it. We discuss how: • AI isn’t a magic bullet for drug discovery. Predictive models lack the physical human data, like individual variation and rare side effects, that can only be generated by actually running real-world clinical trials. • As scientists invent more effective drugs, it becomes harder to discover new treatments that can surpass past successes. This is known as the "Better than the Beatles" problem. • Biotech companies are increasingly moving their "first-in-human" trials to Australia because its simpler regulations allow researchers to test drug safety faster and cheaper than in the US. • Clinical trials can be made more efficient with various reforms including: embracing platform trials, allowing researchers to select from independent ethics boards, expanding the funding and validation of surrogate endpoints, increasing transparency by releasing regulatory correspondence from failed companies, and much more. Timestamps: 00:00:00 Eroom’s law and the paradox of drug development 00:08:03 How clinical trials actually work 00:10:23 The power and controversy of surrogate endpoints 00:14:01 How historical patent laws influenced trial timelines 00:22:46 The Australia advantage and regulatory drag 00:29:08 Institutional review boards (IRBs) and bureaucratic drag 00:32:21 Open science and successful reforms 00:41:49 Our wishlist for clinical trial reforms, and which reforms we *don’t* like 00:53:48 Why AI isn’t a magic bullet for drug discovery
56:13

NEW episode! Drug development has never been more expensive, in terms of output per dollar spent. This trend, called Eroom’s law, is surprising, considering the incredible technological advances in drug discovery, from genome sequencing to engineering to microscopy. On a new episode of the Works in Progress podcast, Ben Southwood and I talk to Ruxandra Teslo 🧬 about why this has happened and what can be done about it. We discuss how: • AI isn’t a magic bullet for drug discovery. Predictive models lack the physical human data, like individual variation and rare side effects, that can only be generated by actually running real-world clinical trials. • As scientists invent more effective drugs, it becomes harder to discover new treatments that can surpass past successes. This is known as the "Better than the Beatles" problem. • Biotech companies are increasingly moving their "first-in-human" trials to Australia because its simpler regulations allow researchers to test drug safety faster and cheaper than in the US. • Clinical trials can be made more efficient with various reforms including: embracing platform trials, allowing researchers to select from independent ethics boards, expanding the funding and validation of surrogate endpoints, increasing transparency by releasing regulatory correspondence from failed companies, and much more. Timestamps: 00:00:00 Eroom’s law and the paradox of drug development 00:08:03 How clinical trials actually work 00:10:23 The power and controversy of surrogate endpoints 00:14:01 How historical patent laws influenced trial timelines 00:22:46 The Australia advantage and regulatory drag 00:29:08 Institutional review boards (IRBs) and bureaucratic drag 00:32:21 Open science and successful reforms 00:41:49 Our wishlist for clinical trial reforms, and which reforms we *don’t* like 00:53:48 Why AI isn’t a magic bullet for drug discovery

Saloni

109,256 views • 4 months ago

🚨New Episode: Please welcome Shiloe Bear to the Fort! As the founder of Creek Development, Shiloe has completed 63 commercial redevelopment projects and 5 land entitlement plays in the San Francisco Bay Area. Leveraging her deep construction expertise, she challenges project assumptions and incorporates impactful design to achieve remarkable outcomes for her clients and investors. We discuss: - Building Creek as an outsourced developer - Converting industrial buildings into biotech lab space - A deep dive into the Bay Area RE market - Why design is such an important aspect of development 00:00:00 - Intro 00:01:11 - Shiloe’s upbringing and journey to doing development in the Bay Area 00:08:25 - What are the projects you work on the most? 00:11:01 - Why is there such a demand for outsourced development? 00:11:47 - What makes your firm different? 00:16:50 - Minimum Viable Projects 00:21:47 - How early in a project do you need to be brought in? 00:25:14 - What are some obvious parts of a project where you can save money? 00:27:30 - How would you describe the Bay Area market right now? 00:33:35 - Office to Residential 00:37:46 - What’s the environment like for Oakland? 00:42:31 - How Shiloe is planning to pivot her business into doing their own developments 00:47:51 - How important are the relationships you’ve developed in The Bay over the past 10 years? 00:53:06 - The BioTech market and development strategy 01:00:55 - Why design matters 01:08:27 - How far out are labs looking for space? 01:09:46 - Lenders, Leases, and hold periods 01:12:36 - Why did this become your niche? 01:14:13 - Shiloe’s bird-watching skills & long-distance running
1:17:35

🚨New Episode: Please welcome Shiloe Bear to the Fort! As the founder of Creek Development, Shiloe has completed 63 commercial redevelopment projects and 5 land entitlement plays in the San Francisco Bay Area. Leveraging her deep construction expertise, she challenges project assumptions and incorporates impactful design to achieve remarkable outcomes for her clients and investors. We discuss: - Building Creek as an outsourced developer - Converting industrial buildings into biotech lab space - A deep dive into the Bay Area RE market - Why design is such an important aspect of development 00:00:00 - Intro 00:01:11 - Shiloe’s upbringing and journey to doing development in the Bay Area 00:08:25 - What are the projects you work on the most? 00:11:01 - Why is there such a demand for outsourced development? 00:11:47 - What makes your firm different? 00:16:50 - Minimum Viable Projects 00:21:47 - How early in a project do you need to be brought in? 00:25:14 - What are some obvious parts of a project where you can save money? 00:27:30 - How would you describe the Bay Area market right now? 00:33:35 - Office to Residential 00:37:46 - What’s the environment like for Oakland? 00:42:31 - How Shiloe is planning to pivot her business into doing their own developments 00:47:51 - How important are the relationships you’ve developed in The Bay over the past 10 years? 00:53:06 - The BioTech market and development strategy 01:00:55 - Why design matters 01:08:27 - How far out are labs looking for space? 01:09:46 - Lenders, Leases, and hold periods 01:12:36 - Why did this become your niche? 01:14:13 - Shiloe’s bird-watching skills & long-distance running

Chris Powers

64,474 views • 3 years ago

Since the start of the year, OpenCode (YC W21) — an open source alternative to Claude Code and Codex that works with any model — exploded to 4.6 million weekly active users, 13 million monthly actives, and roughly $40M in annualized revenue. In this episode of The Lightcone, Harj Taggar, Jared Friedman, and Diana talk with Jay V (Jay), OpenCode’s CEO, about what’s driving this wild growth, the Anthropic clampdown that inadvertently fueled it, and the almost 20 year founder journey that led him here. 00:44 — OpenCode’s Explosive Growth 01:16 — 20x Growth, 13M Users, and 7 Trillion Tokens 03:39 — The Anthropic Controversy That Changed Everything 05:43 — Bringing AI Coding Agents to the World 06:39 — When Open Source Models Became Good Enough 08:56 — What Millions of Developers Are Actually Using 13:31 — Why OpenCode Is Huge Outside the US 15:27 — Why Fortune 500 Companies Choose OpenCode 16:36 — The Economics of AI Tokens 20:02 — How Enterprises Are Using Coding Agents 22:58 — AI’s New Unit Economics 24:56 — Why Model Choice Matters 29:55 — The Product Decisions Behind OpenCode 34:21 — A 16-Year Overnight Success 41:16 — Why Jay Never Gave Up
44:26

Since the start of the year, OpenCode (YC W21) — an open source alternative to Claude Code and Codex that works with any model — exploded to 4.6 million weekly active users, 13 million monthly actives, and roughly $40M in annualized revenue. In this episode of The Lightcone, Harj Taggar, Jared Friedman, and Diana talk with Jay V (Jay), OpenCode’s CEO, about what’s driving this wild growth, the Anthropic clampdown that inadvertently fueled it, and the almost 20 year founder journey that led him here. 00:44 — OpenCode’s Explosive Growth 01:16 — 20x Growth, 13M Users, and 7 Trillion Tokens 03:39 — The Anthropic Controversy That Changed Everything 05:43 — Bringing AI Coding Agents to the World 06:39 — When Open Source Models Became Good Enough 08:56 — What Millions of Developers Are Actually Using 13:31 — Why OpenCode Is Huge Outside the US 15:27 — Why Fortune 500 Companies Choose OpenCode 16:36 — The Economics of AI Tokens 20:02 — How Enterprises Are Using Coding Agents 22:58 — AI’s New Unit Economics 24:56 — Why Model Choice Matters 29:55 — The Product Decisions Behind OpenCode 34:21 — A 16-Year Overnight Success 41:16 — Why Jay Never Gave Up

Y Combinator

753,746 views • 1 month ago

Today’s guest on the Free Radicals podcast is Michael Ringel, JD PhD, COO Life Biosciences and former Managing Director at Boston Consulting Group. Michael is a leader in longevity and pharma who spent 25+ years advising top pharma companies on their R&D strategy. He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry. In this episode, we discuss Michael’s insightful paper on why aging is an optimization by evolution, why that means it’s malleable, and how to push the longevity field forward. Michael also sits on the US board of Hevolution Foundation and on the board of the AFAR. Be sure to follow me and Eric Dai to stay up to date on the latest news in longevity biotech! 0:00 Intro 2:30 Why aging is an optimization by evolution 15:10 Why scientists miss the role of evolution in aging 19:31 Evidence that aging is a regulated process 24:40 Hormesis and adaptive stress responses 28:55 The promise of partial epigenetic reprogramming in humans 35:08 Life Bio's first therapy proceeding to clinical trials 47:47 Why targeting the eye, particularly glaucoma and NION, is a strategic choice 52:03 The pharma industry's perspective on anti-aging research 56:39 The importance of public engagement for funding and policy change 1:05:42 Reasons for optimism in longevity 1:08:26 Advice on how to have an impactful and interdisciplinary career 1:11:54 The ethical case for longevity 1:17:34 Concrete steps for audience members to support longevity research
1:20:44

Today’s guest on the Free Radicals podcast is Michael Ringel, JD PhD, COO Life Biosciences and former Managing Director at Boston Consulting Group. Michael is a leader in longevity and pharma who spent 25+ years advising top pharma companies on their R&D strategy. He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry. In this episode, we discuss Michael’s insightful paper on why aging is an optimization by evolution, why that means it’s malleable, and how to push the longevity field forward. Michael also sits on the US board of Hevolution Foundation and on the board of the AFAR. Be sure to follow me and Eric Dai to stay up to date on the latest news in longevity biotech! 0:00 Intro 2:30 Why aging is an optimization by evolution 15:10 Why scientists miss the role of evolution in aging 19:31 Evidence that aging is a regulated process 24:40 Hormesis and adaptive stress responses 28:55 The promise of partial epigenetic reprogramming in humans 35:08 Life Bio's first therapy proceeding to clinical trials 47:47 Why targeting the eye, particularly glaucoma and NION, is a strategic choice 52:03 The pharma industry's perspective on anti-aging research 56:39 The importance of public engagement for funding and policy change 1:05:42 Reasons for optimism in longevity 1:08:26 Advice on how to have an impactful and interdisciplinary career 1:11:54 The ethical case for longevity 1:17:34 Concrete steps for audience members to support longevity research

Daniel Shur

16,988 views • 5 months ago

Brex co-founder and CEO Pedro Franceschi believes most people still underestimate how much AI will change the way companies are built. AI isn't just another tool, it's a new foundation for building products, teams, and companies. In this episode of Lightcone Podcast, Pedro Franceschi explains why we're only months into a platform shift as significant as the invention of electricity, why the CEO needs to be the chief AI officer, and why founders should rethink what's possible when intelligence is available on demand. 01:13 – How Pedro Became AI-Pilled 04:08 – The Electricity Analogy 05:21 – Free the Claw 06:56 – Making AI Safe for Enterprise 10:57 – Why Most Companies Are Behind 13:09 – AI Teammates, Not Chatbots 14:22 – The Case for Tokenmaxxing 18:24 – The Company of One 20:54 – The One Thing AI Can't Replace 28:06 – Building Customer World Models 32:58 – Rebuilding Brex Around AI 39:02 – The CEO Must Be the Chief AI Officer 43:50 – Building Company AGI 51:43 – Why We're Still So Early
54:06

Brex co-founder and CEO Pedro Franceschi believes most people still underestimate how much AI will change the way companies are built. AI isn't just another tool, it's a new foundation for building products, teams, and companies. In this episode of Lightcone Podcast, Pedro Franceschi explains why we're only months into a platform shift as significant as the invention of electricity, why the CEO needs to be the chief AI officer, and why founders should rethink what's possible when intelligence is available on demand. 01:13 – How Pedro Became AI-Pilled 04:08 – The Electricity Analogy 05:21 – Free the Claw 06:56 – Making AI Safe for Enterprise 10:57 – Why Most Companies Are Behind 13:09 – AI Teammates, Not Chatbots 14:22 – The Case for Tokenmaxxing 18:24 – The Company of One 20:54 – The One Thing AI Can't Replace 28:06 – Building Customer World Models 32:58 – Rebuilding Brex Around AI 39:02 – The CEO Must Be the Chief AI Officer 43:50 – Building Company AGI 51:43 – Why We're Still So Early

Y Combinator

198,967 views • 3 months ago

In this episode of the Lightcone Podcast, we sat down with Mukund Jha and Madhav Jha, the founders of Emergent - an AI platform that lets anyone build and ship production-ready software. In just eight months, users have created more than 7 million apps on Emergent, with the number doubling in just the last 45 days. We discuss how they built one of the most powerful AI coding agents, why they focused on non-technical users and what it's like building for a global audience from India. 00:00 - Intro 01:06 - What Is Emergent? 01:18 - Founder Backstory 02:09 - From AI Testing to General Coding Agents 02:52 - Getting Ahead of the Market 04:18 - The Pivot to Non-Technical Users 05:22 - Why Second Movers Can Win in AI 09:04 - Building for Production, Not Just Prototypes 18:21 - Live Demo: Building Apps with Emergent 24:40 - How Emergent Hires and Runs a Lean Team 29:04 - Is SaaS Dead? The Rise of Personalized Software 34:04 - The Future: Niche Apps, Solo Builders and AI Agency
39:32

In this episode of the Lightcone Podcast, we sat down with Mukund Jha and Madhav Jha, the founders of Emergent - an AI platform that lets anyone build and ship production-ready software. In just eight months, users have created more than 7 million apps on Emergent, with the number doubling in just the last 45 days. We discuss how they built one of the most powerful AI coding agents, why they focused on non-technical users and what it's like building for a global audience from India. 00:00 - Intro 01:06 - What Is Emergent? 01:18 - Founder Backstory 02:09 - From AI Testing to General Coding Agents 02:52 - Getting Ahead of the Market 04:18 - The Pivot to Non-Technical Users 05:22 - Why Second Movers Can Win in AI 09:04 - Building for Production, Not Just Prototypes 18:21 - Live Demo: Building Apps with Emergent 24:40 - How Emergent Hires and Runs a Lean Team 29:04 - Is SaaS Dead? The Rise of Personalized Software 34:04 - The Future: Niche Apps, Solo Builders and AI Agency

Y Combinator

107,806 views • 6 months ago

"A week is 2% of the year. The cadence we operate on is: A week is not the shortest timeline. It's the longest timeline. What can we decide by tomorrow?" - Michael Grinich. Michael Grinich. Founder and CEO of WorkOS. The company powering the enterprise adoption of AI. Knuckle Up ↓ -- 00:00 Introduction 01:33 From design-obsessed founder to enterprise infrastructure 04:20 Michael’s year off and what made the WorkOS bet obvious 06:54 Why a great startup idea has to look bad first 09:46 Minimum awesome product beats MVP 11:09 The org with no CRO, no VP of sales, and one PM 13:29 Hiring for curiosity, not credentials 16:25 The "AI pilled" interview red flag 18:25 A week is 2% of the year 26:00 How WorkOS approaches brand 33:00 The future shape of engineering orgs 43:20 Why senior engineers benefit most from AI 44:45 Micro-leadership over micromanagement 49:10 Tough times in the early days 59:04 The reverse Peter principle 1:04:38 Quickfire: red flags, hires too early, and biggest fears 1:10:30 Michael's advice to his 25-year-old self
1:12:20

"A week is 2% of the year. The cadence we operate on is: A week is not the shortest timeline. It's the longest timeline. What can we decide by tomorrow?" - Michael Grinich. Michael Grinich. Founder and CEO of WorkOS. The company powering the enterprise adoption of AI. Knuckle Up ↓ -- 00:00 Introduction 01:33 From design-obsessed founder to enterprise infrastructure 04:20 Michael’s year off and what made the WorkOS bet obvious 06:54 Why a great startup idea has to look bad first 09:46 Minimum awesome product beats MVP 11:09 The org with no CRO, no VP of sales, and one PM 13:29 Hiring for curiosity, not credentials 16:25 The "AI pilled" interview red flag 18:25 A week is 2% of the year 26:00 How WorkOS approaches brand 33:00 The future shape of engineering orgs 43:20 Why senior engineers benefit most from AI 44:45 Micro-leadership over micromanagement 49:10 Tough times in the early days 59:04 The reverse Peter principle 1:04:38 Quickfire: red flags, hires too early, and biggest fears 1:10:30 Michael's advice to his 25-year-old self

Nakul Mandan

671,989 views • 4 months ago

New Infinite Loops with Saloni Dattani (Saloni)! There may be medical breakthroughs in the pipeline right now that work — but won’t reach patients for another decade. Saloni Dattani joins us to explain the hidden bottleneck slowing the future of medicine and why biology may be one of the most important fields to work in today. Listen now. TIMESTAMPS: 0:00 Intro 2:07 The Problem with Health Data 14:44 Clinical Trials Are the Bottleneck 25:05 AI and Drug Discovery 35:00 Why Science Journalism Fails 45:41 Medicine’s Next Great Leap 50:20 Fixing Medical Market Failures 57:10 The Leukemia Trial Breakthrough 1:06:18 Why Failed Research Matters 1:12:51 Science Is Never Settled
1:25:53

New Infinite Loops with Saloni Dattani (Saloni)! There may be medical breakthroughs in the pipeline right now that work — but won’t reach patients for another decade. Saloni Dattani joins us to explain the hidden bottleneck slowing the future of medicine and why biology may be one of the most important fields to work in today. Listen now. TIMESTAMPS: 0:00 Intro 2:07 The Problem with Health Data 14:44 Clinical Trials Are the Bottleneck 25:05 AI and Drug Discovery 35:00 Why Science Journalism Fails 45:41 Medicine’s Next Great Leap 50:20 Fixing Medical Market Failures 57:10 The Leukemia Trial Breakthrough 1:06:18 Why Failed Research Matters 1:12:51 Science Is Never Settled

Infinite Loops 🎙

11,818 views • 4 months ago

Last month Moderna reported the first individualized cancer vaccine to pass a Phase 3. Moderna CEO Stéphane Bancel and a16z's Jorge Conde on what that actually means: The treatment works by sequencing a patient’s tumor and healthy cells, identifying the mutations relevant to their cancer, and encoding up to 34 of them into an mRNA specific to the individual. Rather than simply unleashing the immune system, the goal is to teach it what to recognize and attack. In this conversation, they unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. 00:00 Intro 02:35 A Phase 3 that beat the standard of care 06:00 Why today's immunotherapy fails 40% of patients 09:35 A vaccine for cancer you already have 11:20 Why mRNA worked where 1,000 trials failed 13:15 90% of cancer antigens are unique to you 16:35 Why this vaccine only gets better from here 21:00 The only thing Moderna needs is your DNA sequence 22:20 Why the first robot was intentionally inefficient 27:10 How the FDA approves a drug that's different every time 33:05 A cancer treatment with the side effects of a flu shot 33:30 Why pancreatic cancer is worth a risk 36:30 Rare liver disease next, then autoimmune YouTube: Moderna Jorge Conde
38:53

Last month Moderna reported the first individualized cancer vaccine to pass a Phase 3. Moderna CEO Stéphane Bancel and a16z's Jorge Conde on what that actually means: The treatment works by sequencing a patient’s tumor and healthy cells, identifying the mutations relevant to their cancer, and encoding up to 34 of them into an mRNA specific to the individual. Rather than simply unleashing the immune system, the goal is to teach it what to recognize and attack. In this conversation, they unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. 00:00 Intro 02:35 A Phase 3 that beat the standard of care 06:00 Why today's immunotherapy fails 40% of patients 09:35 A vaccine for cancer you already have 11:20 Why mRNA worked where 1,000 trials failed 13:15 90% of cancer antigens are unique to you 16:35 Why this vaccine only gets better from here 21:00 The only thing Moderna needs is your DNA sequence 22:20 Why the first robot was intentionally inefficient 27:10 How the FDA approves a drug that's different every time 33:05 A cancer treatment with the side effects of a flu shot 33:30 Why pancreatic cancer is worth a risk 36:30 Rare liver disease next, then autoimmune YouTube: Moderna Jorge Conde

a16z

72,421 views • 15 days ago

NEW: How AWS Sold Cloud Computing to the CIA (and legitimized it for the entire world.) Teresa Carlson built AWS Public Sector from $0 to $10 Billion in Revenue in 10 years Now, as Founding CEO of General Catalyst Institute, she's helping startups gain an unfair advantage. Teresa breaks down the deal that defined cloud — & what AI likely needs to do next. We cover: → How AWS won the CIA contract → Lessons from Jeff Bezos & Andy Jassy → One-way vs two-way doors as a decision framework → Why AI is a "double or triple-strap-in" cloud → How startups actually win in DC today → The case for a federal AI framework → Inside the General Catalyst Institute Teresa Carlson General Catalyst 𝐓𝐈𝐌𝐄𝐒𝐓𝐀𝐌𝐏𝐒 (00:00) Teresa Carlson, Founding CEO at GCI (01:08) The historic Kentucky Derby win (02:38) $10B AWS blueprint (04:56) Converting the skeptics (12:03) Contract that changed the trajectory of AWS (17:05) Building a world-class team (24:01) The scaling mantra (29:12) Lessons from Jeff Bezos & Andy Jassy (35:33) Why is AI scaling scaring governments? (40:23) Surviving the AI debt trap (44:56) Why do government deals matter? (48:55) Founding the General Catalyst Institute with Hemant Taneja (Hemant Taneja) (54:49) Founders storming Capitol Hill (59:53) The unspoken rule of DC (01:05:53) The next big AI shockwave
1:07:58

NEW: How AWS Sold Cloud Computing to the CIA (and legitimized it for the entire world.) Teresa Carlson built AWS Public Sector from $0 to $10 Billion in Revenue in 10 years Now, as Founding CEO of General Catalyst Institute, she's helping startups gain an unfair advantage. Teresa breaks down the deal that defined cloud — & what AI likely needs to do next. We cover: → How AWS won the CIA contract → Lessons from Jeff Bezos & Andy Jassy → One-way vs two-way doors as a decision framework → Why AI is a "double or triple-strap-in" cloud → How startups actually win in DC today → The case for a federal AI framework → Inside the General Catalyst Institute Teresa Carlson General Catalyst 𝐓𝐈𝐌𝐄𝐒𝐓𝐀𝐌𝐏𝐒 (00:00) Teresa Carlson, Founding CEO at GCI (01:08) The historic Kentucky Derby win (02:38) $10B AWS blueprint (04:56) Converting the skeptics (12:03) Contract that changed the trajectory of AWS (17:05) Building a world-class team (24:01) The scaling mantra (29:12) Lessons from Jeff Bezos & Andy Jassy (35:33) Why is AI scaling scaring governments? (40:23) Surviving the AI debt trap (44:56) Why do government deals matter? (48:55) Founding the General Catalyst Institute with Hemant Taneja (Hemant Taneja) (54:49) Founders storming Capitol Hill (59:53) The unspoken rule of DC (01:05:53) The next big AI shockwave

Molly O’Shea

78,617 views • 4 months ago

Bitcoin BREAKOUT Could Be Just the Start - AI May Reallocate $50 TRILLION | Bill Barhydt 00:00 Bitcoin Finally Breaks Out 01:12 Why Trump’s Policies Are Bullish for Bitcoin 05:22 The U.S. Debt Problem and the Battle With China 08:12 Why Trump Wants Lower Rates 11:59 Is Bitcoin’s Four-Year Cycle Still Alive? 15:55 Trump, Hyperliquid and the Future of Perps 17:38 Why Everything Is Becoming Tradable on Crypto 19:30 Bill Reveals What Abra Is Building Next 22:34 Where the Yield on Bitcoin Actually Comes From 26:44 The Financialization of Crypto Is Here 28:02 What Comes After Tokenization 32:57 The $50 Trillion Wealth Reallocation 33:26 Will AI Replace Financial Advisors? 35:30 Why 24/7 Markets Need AI 36:40 Bitcoin’s Role in an AI-Driven Financial System 39:09 Ethereum vs. Solana and the Future of Blockchains 42:00 What Happens When AI and Crypto Truly Merge? 46:06 Will Humans Eventually Merge With AI? 47:54 “AI Is Never Going to Be Dumber Than It Is Now” 49:02 Are Million-Dollar Bitcoin Targets Still Realistic? 49:38 Why Bitcoin Could Become the World’s Pristine Collateral
51:26

Bitcoin BREAKOUT Could Be Just the Start - AI May Reallocate $50 TRILLION | Bill Barhydt 00:00 Bitcoin Finally Breaks Out 01:12 Why Trump’s Policies Are Bullish for Bitcoin 05:22 The U.S. Debt Problem and the Battle With China 08:12 Why Trump Wants Lower Rates 11:59 Is Bitcoin’s Four-Year Cycle Still Alive? 15:55 Trump, Hyperliquid and the Future of Perps 17:38 Why Everything Is Becoming Tradable on Crypto 19:30 Bill Reveals What Abra Is Building Next 22:34 Where the Yield on Bitcoin Actually Comes From 26:44 The Financialization of Crypto Is Here 28:02 What Comes After Tokenization 32:57 The $50 Trillion Wealth Reallocation 33:26 Will AI Replace Financial Advisors? 35:30 Why 24/7 Markets Need AI 36:40 Bitcoin’s Role in an AI-Driven Financial System 39:09 Ethereum vs. Solana and the Future of Blockchains 42:00 What Happens When AI and Crypto Truly Merge? 46:06 Will Humans Eventually Merge With AI? 47:54 “AI Is Never Going to Be Dumber Than It Is Now” 49:02 Are Million-Dollar Bitcoin Targets Still Realistic? 49:38 Why Bitcoin Could Become the World’s Pristine Collateral

The Wolf Of All Streets

39,959 views • 24 days ago

Instinct is the AI assistant every VC is chasing. Its founder, Noah Shinn, co-wrote Reflexion, one of the earliest agentic frameworks with MIT's Ashwin Gopinath. Noah chose to build agents for individuals. Ashwin quietly went the other way and founded Sentra to bring memory to enterprise agents. Sentra is now the company brain of a $12B public company-- 18,000 employees, and the CXOs start their day on it. Nothing like it exists in public. I sat down with Ashwin at Land's End in San Francisco before any of this was revealed. We got into: •Why memory is not a knowledge base •Why organizational memory is easier to build than individual memory •Why he thinks the AI race is nowhere near over •Who's actually accountable when AI gets something wrong •What worries him about his daughter growing up unable to tell AI from a person 𝐓𝐈𝐌𝐄𝐒𝐓𝐀𝐌𝐏𝐒 (00:00) Meet Ashwin at Land's End (00:48) What Sentra Builds (03:53) Why Agents Need Memory (06:44) Memory vs. Knowledge Base (08:38) Why Org Memory Works (13:02) Who's Accountable When AI Gets It Wrong (15:36) Humans Becoming AI (18:52) The AI Race Is Not Over (29:43) Choosing the Right Team (36:10) The AI Transition and Perspective (39:34) Kids Growing Up With AI (46:09) Agency as the Edge
48:54

Instinct is the AI assistant every VC is chasing. Its founder, Noah Shinn, co-wrote Reflexion, one of the earliest agentic frameworks with MIT's Ashwin Gopinath. Noah chose to build agents for individuals. Ashwin quietly went the other way and founded Sentra to bring memory to enterprise agents. Sentra is now the company brain of a $12B public company-- 18,000 employees, and the CXOs start their day on it. Nothing like it exists in public. I sat down with Ashwin at Land's End in San Francisco before any of this was revealed. We got into: •Why memory is not a knowledge base •Why organizational memory is easier to build than individual memory •Why he thinks the AI race is nowhere near over •Who's actually accountable when AI gets something wrong •What worries him about his daughter growing up unable to tell AI from a person 𝐓𝐈𝐌𝐄𝐒𝐓𝐀𝐌𝐏𝐒 (00:00) Meet Ashwin at Land's End (00:48) What Sentra Builds (03:53) Why Agents Need Memory (06:44) Memory vs. Knowledge Base (08:38) Why Org Memory Works (13:02) Who's Accountable When AI Gets It Wrong (15:36) Humans Becoming AI (18:52) The AI Race Is Not Over (29:43) Choosing the Right Team (36:10) The AI Transition and Perspective (39:34) Kids Growing Up With AI (46:09) Agency as the Edge

Julia Fedorin

33,811 views • 8 days ago